Home/Pipeline/Multiple Obesity Programs

Multiple Obesity Programs

Obesity

DiscoveryActive

Key Facts

Indication

Obesity

Phase

Discovery

Status

Active

Company

Confo Therapeutics

About Confo Therapeutics

Confo Therapeutics is a Belgian clinical-stage biotech pioneering a unique approach to drug discovery for GPCRs, a historically challenging but highly druggable target class. The company's proprietary platform enables the development of both small molecules and antibodies, with a pipeline focused on metabolic and endocrine conditions, including neuropathic pain, obesity, and post-bariatric hypoglycemia. Backed by a €60M Series B financing and strategic partnerships, Confo is advancing its lead candidate, CFTX-1554, into Phase 1 while expanding its early-stage pipeline. The company operates as a private, pre-revenue entity leveraging its technology for internal programs and potential collaborations.

View full company profile

Therapeutic Areas

Metabolic Diseases Endocrine Diseases Pain

Other Obesity Drugs

Drug	Company	Phase	Status
Tirzepatide (Zepbound)	Eli Lilly	Approved	Commercial
APJ Program	BioAge Labs	Preclinical	Active
Wegovy HD (semaglutide 7.2mg)	Novo Nordisk	Approved	Recently approved in US
Amylin analogue (subcutaneous)	Novo Nordisk	Phase 1	Active
GLP1-GIP-Amylin tri-agonist	Novo Nordisk	Phase 2	Active
VK2735 (subcutaneous)	Viking Therapeutics	Phase 3	Active
VK2735 (oral)	Viking Therapeutics	Phase 1/2	Active
GSBR-1290	Structure Therapeutics	Phase 2	Active, not recruiting
LTSE-2578	Structure Therapeutics	Preclinical	Lead Optimization
Survodutide (BI 456906)	Zealand Pharma	Phase 3	Active
ZP8396	Zealand Pharma	Preclinical/Phase 1	Active
Pemvidutide (ALT-801)	Altimmune	Phase 2	Active